Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation

BACKGROUND: Activating PIK3CA mutations occur in 20-30% of patients with metastatic breast cancer (mBC). A recent study showed that alpha selective PI3K inhibitors improve outcome in patients with PIK3CA mutation, HR+/Her2- mBC. There is a need to better understand the natural history of PIK3CA muta...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2019-07, Vol.79 (13_Supplement), p.4895-4895
Main Authors: Mosele, Fernanda, Verret, Benjamin, Lusque, Amelie, Filleron, Thomas, Bachelot, Thomas, Arnedos, Monica, Campone, Mario, Dalenc, Florence, Lefeuvre, Claudia, Sablin, Marie Paule, Bonnefoi, Hervé, Lacroix, Ludovic, Bièche, Ivan, Gonçalves, Anthony, Jacot, William, Jimenez, Marta, Jacquet, Amelie, Andre, Fabrice
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Activating PIK3CA mutations occur in 20-30% of patients with metastatic breast cancer (mBC). A recent study showed that alpha selective PI3K inhibitors improve outcome in patients with PIK3CA mutation, HR+/Her2- mBC. There is a need to better understand the natural history of PIK3CA mutant mBC to optimally position of this drug family. PATIENTS AND METHODS: 649 patients from SAFIR02 trial (NCT02299999), for which mutational profile was available and with clinical data entered in a database, were selected for this analysis. Associations between PIK3CA mutation, clinical characteristics and outcome were analyzed. RESULTS: 143 patients (22%) harbor PIK3CA mutation in tumor sample. 10% (n=27) and 34% (n=104) of TNBC and HR+/Her2- mBC presented a PIK3CA mutation respectively (p
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2019-4895